

Michigan Collaborative Standardization of Compounded Oral Liquids

| | | | |
|-----------------------|------------------|----------------------------|--|
| Drug name: | Rifaximin | Dosage Form: | Suspension |
| Concentration: | 20 mg/mL | Shelf Life: | 60 days |
| Route: | Oral | Storage: | Room temperature |
| Volume: | 60 mL | Auxiliary Labeling: | Shake well before use, protect from light |

| Ingredients | QS | Quantity | Units |
|--------------------------|----|----------|--------|
| Rifaximin 200-mg tablets | | 6 | tablet |
| Ora-Sweet | Y | 30 | mL |
| Ora-Plus | Y | 30 | mL |

Directions:

1. Triturate six rifaximin tablets into a fine powder in a glass mortar.
2. Mix equal quantities of Ora-Plus and Ora-Sweet in geometric proportions with constant stirring to produce 60 mL.
3. Using 30 mL of this mixture, levigate the powder into a smooth suspension, adding the vehicle in geometric proportions.
4. Transfer the suspension to a 2-oz child-resistant amber prescription bottle.
5. Rinse the mortar and pestle with sufficient vehicle to bring the final volume in the bottle to 60 mL.

References:

- Nahata MC, Pai VB. Pediatric Drug Formulations. 6th ed. Harvey Whitney Books. Cincinnati, OH, 2011.

Reviewed: April 2013; BW/ME

The information provided on this site is only to be used for educational and informational purposes only. It may not be relied upon to direct or provide care to a patient, or to prepare treatments for a patient. This material is not intended as a substitute for retaining and consulting appropriate medical and health care professionals, who remain solely responsible to provide and direct patient care. Be aware that the information contained on this site may not be up to date due to more recent medical developments. The preparation, dispensing, and administration of pharmaceuticals is and remains the responsibility of licensed medical professionals or pharmacists, and may require governmental approvals. The owner and provider of this site disclaims and assumes no liability for any injury and/or damage to persons from use of any information contained on this site.